Safety and efficacy of hematopoietic and mesanchymal stem cell therapy for treatment of T1DM: a systematic review and meta-analysis protocol

作者：Sedigheh Madani, Bagher Larijani, Abbasali Keshtkar, Ali Tootee · 发表于：Systematic Reviews · 年份：2018 · DOI：10.1186/s13643-017-0662-9 · 被引用次数：8 · 研究领域：Pancreatic function and diabetes、Diabetes Management and Research、Mesenchymal stem cell research

Insulin standard treatment of T1DM cannot cure the patients as different chronic complications occurred subsequently. Investigations on a curative treatment in T1DM propose cell replacement or maintenance instead of exogenous insulin therapy, but different dimensions of this novel treatment are not clarified. We will include all clinical trials which have evaluated the efficacy MSC or HSC transplantation in T1DM treatment; electronically search bibliographic databases, country registration data banks, and gray literatures; and hand-search two key journals, two experts’ article, and references of the included articles with no language restriction. Primary outcome is the extent of reduction in insulin requirement and secondary outcomes are safety of MSC and HSC therapy, effect of this therapy on diabetic parameters, effect of the rout of transplantation and origin of the MSC or HSC on efficacy of treatment, studies heterogeneity and potential reasons of it. Heterogeneity and its severity will be calculated with Q Cochrane test, P value, and I 2 index. STATA software version 12 will be used for meta-analysis. PROSPERO Registration number: CRD42016047176. We will publish the systematic review in a peer review journal; as it presents an analysis of published literature, the study does not require ethical approval. This systematic review and meta-analysis will investigate the efficacy of MSC and HSC transplantation in T1DM treatment with no language restriction. Also we will evalua...